SITE015-0308

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2023-03-02

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-03-23 (study day 9); relationship: not assessed

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-05-21 (study day 68); relationship: not assessed

severe assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-05-22 (study day 69); relationship: Y

severe serious assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-05-31 (study day 78); relationship: not assessed; serious criteria: hospitalization

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-06-03 (study day 81); relationship: not assessed

Data queries

No data queries.